Cargando…

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Around 30% of patients are diagnosed with early disease and 60% after the tumour has spread to a different part of the body. The earlier NSCLC is diagnosed, the better the chances of prolonging survival. Recent years have see...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marchetti, Antonio, Buttitta, Fiamma, D’Angelo, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896216/ https://www.ncbi.nlm.nih.gov/pubmed/35261723 http://dx.doi.org/10.18632/oncotarget.28210

Ejemplares similares

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
por: Zhang, Shu-Ling, et al.
Publicado: (2023)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2016)

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study
por: Duan, Hongxia, et al.
Publicado: (2020)

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022)

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
por: Park, Cheol-Kyu, et al.
Publicado: (2022)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
por: Chen, Caroline Y., et al.
Publicado: (2021)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Diagnostic Workup, Treatment Patterns, and Clinical Outcomes in Early-Stage IB–IIIA Non-Small-Cell Lung Cancer Patients in Denmark
por: Uldbjerg, Ebbe Meldgaard, et al.
Publicado: (2023)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments
por: Marchetti, Antonio, et al.
Publicado: (2019)

Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study)
por: Hilbe, Wolfgang, et al.
Publicado: (2015)

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023)

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units
por: Lazzaro, Carlo, et al.
Publicado: (2023)

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR–ROS1 Fusion
por: Chen, An-guo, et al.
Publicado: (2022)

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
por: Kilvaer, Thomas K., et al.
Publicado: (2015)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC
por: Garitaonaindia, Yago, et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

POLE exonuclease domain mutations in endometrial carcinoma: a case report
por: Pasciuto, Maria Paola, et al.
Publicado: (2023)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
por: Isaka, Tetsuya, et al.
Publicado: (2022)

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
por: Marchetti, Antonio, et al.
Publicado: (2012)

Complete Resolution of Sellar Metastasis in a Patient With NSCLC Treated With Osimertinib
por: Fan, WuQiang, et al.
Publicado: (2019)

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report
por: Hardenberg, M.C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6kbj04vib1usd2ql021edm1d1q